Cargando…

The Year in Review for Renal Cancer

Detalles Bibliográficos
Autor principal:	Vaishampayan, Ulka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Codon Publications 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258384/ https://www.ncbi.nlm.nih.gov/pubmed/32509506 http://dx.doi.org/10.15586/jkcvhl.2020.127

Ejemplares similares

The power of meta-analysis in therapeutic decision making for advanced kidney cancer
por: Vaishampayan, Ulka
Publicado: (2019)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

Surgical Excision of Duodenal/Pancreatic Metastatic Renal Cell Carcinoma
por: Espinoza, Eduardo, et al.
Publicado: (2014)

Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2020)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2022)

Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer
por: Bell, Hannah N., et al.
Publicado: (2022)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth
por: Govindarajan, Barani, et al.
Publicado: (2023)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth
por: Govindarajan, Barani, et al.
Publicado: (2023)

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Renal Transplantation: What Has Changed in Recent Years
por: Santangelo, Michele, et al.
Publicado: (2019)

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
por: Semrad, Thomas J, et al.
Publicado: (2019)

Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinoma
por: Varghese, Bino, et al.
Publicado: (2022)

Renal Revolution: Anticipating the Next 25 Years of India’s Kidney Care
por: Jha, Vivekanand
Publicado: (2023)

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
por: Jeyakumar, Ghayathri, et al.
Publicado: (2017)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Genetics of renal cancer: focus on MTOR
por: Ghosh, Arindam P., et al.
Publicado: (2016)

A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells.
por: Sbrissa, Diego, et al.
Publicado: (2018)

2020: The year in review
por: Ballas, Zuhair K.
Publicado: (2021)

2021: The year in review
por: Ballas, Zuhair K.
Publicado: (2022)

Year in review and appreciation for 2020 reviewers
por: Kim, Sue
Publicado: (2020)

Year in review and appreciation for 2021 reviewers
por: Kim, Sue
Publicado: (2021)

Second-line treatment for renal cell cancer
por: Di Lorenzo, G, et al.
Publicado: (2012)

Immunotherapy in renal cell cancer: the more the merrier?
por: Camarero, Jorge, et al.
Publicado: (2013)

New prognostic models in metastatic renal cancer
por: Lim, Louise, et al.
Publicado: (2012)

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
por: Brown, Jennifer, et al.
Publicado: (2017)

Editorial: 2008 year in review
por: Tseng, Michelle, et al.
Publicado: (2009)

Biophysical Reviews— 2021, the year that was
por: Hall, Damien
Publicado: (2021)

LUNG Year in Review: 2021
por: Dicpinigaitis, Peter V.
Publicado: (2022)

A Year in Review for the IJTMB
por: Kennedy, Ann Blair
Publicado: (2022)

LUNG Year in Review: 2020
por: Dicpinigaitis, Peter V.
Publicado: (2021)

Angiogenesis: a year in review
por: Griffioen, Arjan W., et al.
Publicado: (2021)

LUNG Year in Review: 2022
por: Dicpinigaitis, Peter V.
Publicado: (2023)

Renal cancer: From current evidence to future perspectives
por: Fiori, Cristian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tkr4npf0a8db7t1450lnudvfl9